Penyelidikan Klinik Cleveland baru menunjukkan untuk pertama kalinya bahawa ibrutinib (ibrutinib) yang diluluskan oleh FDA untuk limfoma dan leukemia juga dapat membantu merawat tumor otak yang paling biasa dan mematikan, dan suatu hari boleh digunakan pada pesakit dengan glioblastoma Dan meningkatkan kadar kelangsungan hidup.
Menurut laporan American Brain Tumor Association, kadar survival glioblastoma sangat rendah, dan kelangsungan hidup rata-rata pesakit yang mendapat rawatan standard kurang dari 15 bulan. Glioblastoma adalah tumor otak primer yang paling mematikan dan sangat tahan terhadap rawatan semasa. Terdapat keperluan mendesak untuk memberikan rawatan baru kepada pesakit ini secepat mungkin.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumor in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
